GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN) Files An 8-K Entry into a Material Definitive Agreement

GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Story continues below

Entry into a Material Definitive Agreement.

On July 18, 2017, Great Basin Scientific, Inc. and Spring Forth Investments, LLC (the “Lender”) entered into an Amendment to Spring Forth Promissory Note to which the maturity date of the promissory note issued in favor of the Lender on July 18, 2014 (the “Note”) was extended from July 18, 2017 to July 18, 2018.The remaining terms of the Note remain unchanged.The Lender voluntarily agreed to extend the maturity date.

Item 9.01Financial Statements and Exhibits.

ExhibitNumber

Exhibit Title or Description

10.1*

Amendment to Spring Forth Promissory Note.

*File herewith.


Great Basin Scientific, Inc. Exhibit
EX-10.1 2 gbsn-ex101_6.htm EX-10.1 gbsn-ex101_6.htm Exhibit 10.1 AMENDMENT TO SPRING FORTH PROMISSORY NOTE  This Amendment to Spring Forth Promissory Note (the “Amendment”),…
To view the full exhibit click here

About GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN)

Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.

An ad to help with our costs